Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEM-102 and Rifampin for Prosthetic Joint Infections
NCT01756924Phase 2Terminated
- Sponsor
- Arrevus
- Start
- Dec 2012
- Primary completion
- Jul 2014
- Countries
- 1
01
Overview
A Phase 2 trial of fusidic acid in prosthetic joint infection (PJI), sponsored by Arrevus. Started Dec 2012; status: terminated.
02
Drugs
fusidic acid
03
Conditions
prosthetic joint infection (PJI)
Beyond the preview
Go deeper on NCT01756924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01756924.